Home › Research › Long-term cohort studies
Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline
Cullen N, Janelidze S, Palmqvist S, Stomrud E, Mattsson-Carlgren N, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.. Neurology, 2021-12-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background and objective Experimental studies suggest that the balance between short and long β-amyloid (Aβ) species might modulate the toxic effects of Aβ in Alzheimer disease (AD), but clinical evidence is lacking. We studied whether Aβ 38 levels in CSF relate to risk of AD dementia and cognitive decline. Methods CSF Aβ 38 levels were measured in 656 individuals across 2 clinical cohorts: the Swedish BioFINDER study and the Alzheimer's Disease Neuroimaging Initiative (ADNI).
What this study adds
Evidence grade: Moderate
This is a trial of 656 participants. This study examined whether cerebrospinal fluid levels of a short amyloid-beta species relate to risk of Alzheimer's disease dementia and cognitive decline. It was based on experimental evidence that the balance between short and long amyloid-beta species might affect amyloid-beta toxicity.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Cullen, N., Janelidze, S., Palmqvist, S., Stomrud, E., Mattsson-Carlgren, N., Hansson, O., et al. (2022). Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline. Neurology. https://doi.org/10.1212/wnl.0000000000013228
Vancouver
Cullen N, Janelidze S, Palmqvist S, Stomrud E, Mattsson-Carlgren N, Hansson O, et al. Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline. Neurology. 2022. doi:10.1212/wnl.0000000000013228. PMID: 34937781.
BibTeX
@article{cullen2022-34937781,
author = {Cullen, N. and Janelidze, S. and Palmqvist, S. and Stomrud, E. and Mattsson-Carlgren, N. and Hansson, O. and {Alzheimer’s Disease Neuroimaging Initiative}},
title = {{Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline}},
journal = {Neurology},
year = {2022},
doi = {10.1212/wnl.0000000000013228},
pmid = {34937781},
url = {https://doi.org/10.1212/wnl.0000000000013228}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- We studied whether Aβ 38 levels in CSF relate to risk of AD dementia and cognitive decline.
- Methods CSF Aβ 38 levels were measured in 656 individuals across 2 clinical cohorts: the Swedish BioFINDER study and the Alzheimer's Disease Neuroimaging Initiative (ADNI).
- Cox regression models were used to evaluate the association between baseline Aβ 38 levels and risk of AD dementia in AD biomarker-positive individuals (AD+; determined by CSF phosphorylated tau [P-tau]/Aβ 42 ratio) with subjective cognitive decline (SCD) or mild cognitive impairment (MCI).
- Linear mixed-effects models were used to evaluate the association between baseline Aβ 38 levels and cognitive decline as measured by the Mini-Mental State Examination (MMSE) in AD+ participants with SCD, MCI, or AD dementia.
Why it matters
This study examined whether cerebrospinal fluid levels of a short amyloid-beta species relate to risk of Alzheimer's disease dementia and cognitive decline. It was based on experimental evidence that the balance between short and long amyloid-beta species might affect amyloid-beta toxicity.
Study details
- Participants656
- Evidence strengthModerate
How this study scored 55/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 53 of the 96 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 656 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 43 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.2 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 3 / 6 | Cited 5.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 2 / 4 | Cited 27 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 1 / 3 | Lund University: institution h-index 1,119 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34937781) |
| Free to read | 2 / 2 | Free to read |
| Points | 53 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 53 of the 96 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Long-term cohort studies from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.